Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of California Berkeley
Headquarters: Berkeley, CA, United States of America
Website: http://www.berkeley.edu
Year Founded: 1868
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 2, 2024
Discovery & Translation
Science spotlight: Doudna lab’s cell-penetrating CRISPR RNPs, durable epigenome editing and more
BioCentury’s roundup of translational innovations
BioCentury | Nov 1, 2023
Regulation
Exa-cel meeting clarifies off-target expectations for gene editing therapies
FDA’s advisers were satisfied with the methods used by CRISPR Therapeutics and Vertex to analyze the off-target edits of gene editing therapy exa-cel
BioCentury | Aug 21, 2023
Product Development
Equitable access to new modalities: from innovation to reimbursement
Perspectives from innovators and policy professionals on what it takes to get next-generation technologies to diverse populations
BioCentury | Jul 11, 2023
Finance
Menlo Ventures continues scaling focus on tech-enabled bio
Menlo is looking to invest in generative AI for drug design and problem-solvers for gene editing — and to grow its healthcare team
BioCentury | May 12, 2023
Discovery & Translation
Adding diversity to the human reference genome; SNIPR’s phage and more
BioCentury’s roundup of translational news
BioCentury | May 2, 2023
Finance
May 1 Quick Takes: Acelyrin could be NASDAQ’s biggest biotech IPO in two years
Plus: Translational inhibition company Initial launches with $75M from ATP and updates from Biogen, Ascendis, Minerva, Teva-MedinCell, BMS, Avadel
BioCentury | Mar 17, 2023
Discovery & Translation
RNA origami to aid delivery; plus sense-and-response ADAR base editing and more
BioCentury's roundup of translational news
BioCentury | Mar 14, 2023
Product Development
Gene editing: designing therapies for market access
In vivo stem cell editing and diversification of genomic databases are top research priorities to promote equitable access
BioCentury | Jan 28, 2023
Discovery & Translation
CRISPR knockdown tech from Doudna lab; plus CAR Ts for myasthenia gravis and more
BioCentury’s roundup of translational news
BioCentury | Jan 6, 2023
Emerging Company Profile
BioCentury’s 2022 class of emerging companies
A snapshot of gene therapy and CAR T innovation, the emergence of protein stabilization, and new thinking in neurology
Items per page:
1 - 10 of 307